# Velcade, Nipent, Rituxan (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma

> **NCT01460602** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Louisiana State University Health Sciences Center Shreveport**

## Conditions studied

- Follicular Lymphoma
- Marginal Zone Lymphoma
- Mantle Cell Lymphoma

## Interventions

- **DRUG:** MTD of Velcade, Nipent and Rituxan established in Part 1

## Key facts

- **NCT ID:** NCT01460602
- **Lead sponsor:** Louisiana State University Health Sciences Center Shreveport
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2010-05
- **Primary completion:** 2014-10
- **Final completion:** 2014-10
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Investigator has relocated to MD Anderson
- **Last updated:** 2020-09-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01460602

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01460602, "Velcade, Nipent, Rituxan (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01460602. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*